Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

Detalles Bibliográficos
Autores principales: Kim, Sunkyu, Tiedt, Ralph, Loo, Alice, Horn, Thomas, Delach, Scott, Kovats, Steven, Haas, Kristy, Engstler, Barbara Schacher, Cao, Alexander, Pinzon-Ortiz, Maria, Mulford, Iain, Acker, Michael G., Chopra, Rajiv, Brain, Christopher, Tomaso, Emmanuelle di, Sellers, William R., Caponigro, Giordano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147087/
https://www.ncbi.nlm.nih.gov/pubmed/32292577
http://dx.doi.org/10.18632/oncotarget.27407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147087/
https://www.ncbi.nlm.nih.gov/pubmed/32292577
http://dx.doi.org/10.18632/oncotarget.27407

Ejemplares similares